The Anti-Tumor Effect of Nab-Paclitaxel Proven by Patient-Derived Organoids.

Xing XiaoWei ChenZhe-Wei WeiWei-Wei ChuXiao-Fang LuBo LiHong ChenSi-Jun MengTeng-Fei HaoJi-Tao WeiYu-Long HeChang-Hua Zhang

Published in: OncoTargets and therapy (2020)

Nab-paclitaxel showed strong anti-tumor activity and had the potential to become front-line drug for treating GC patients. Gastric cancer organoid may be a good tool to predict in vivo response to drugs.

Keyphrases

end stage renal disease
ejection fraction
advanced non small cell lung cancer
prognostic factors
peritoneal dialysis
emergency department
patient reported outcomes